Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) have received a consensus recommendation of "Hold" from the nineteen brokerages that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, fifteen have given a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $8.88.
A number of brokerages have recently commented on SAGE. Needham & Company LLC reissued a "hold" rating on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Royal Bank of Canada upgraded shares of Sage Therapeutics from an "underperform" rating to a "sector perform" rating and set a $4.00 price target for the company in a report on Thursday, November 21st. HC Wainwright reissued a "neutral" rating and issued a $12.00 price objective (down from $14.00) on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Wedbush reaffirmed a "neutral" rating and set a $6.00 price objective on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Finally, TD Cowen lowered their target price on shares of Sage Therapeutics from $10.00 to $9.00 and set a "hold" rating for the company in a research note on Thursday, November 21st.
Get Our Latest Research Report on SAGE
Sage Therapeutics Stock Up 0.4 %
SAGE stock traded up $0.03 during midday trading on Monday, hitting $7.58. The company's stock had a trading volume of 1,266,436 shares, compared to its average volume of 2,166,078. The firm has a 50-day simple moving average of $6.87 and a 200-day simple moving average of $6.75. The firm has a market capitalization of $466.03 million, a P/E ratio of -1.15 and a beta of 0.94. Sage Therapeutics has a 52-week low of $4.62 and a 52-week high of $22.34.
Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. On average, sell-side analysts expect that Sage Therapeutics will post -3.52 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Sage Therapeutics
A number of large investors have recently added to or reduced their stakes in the business. RTW Investments LP lifted its holdings in shares of Sage Therapeutics by 2.0% in the third quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company's stock valued at $40,372,000 after purchasing an additional 111,123 shares in the last quarter. Caligan Partners LP acquired a new position in shares of Sage Therapeutics during the 4th quarter worth approximately $16,575,000. State Street Corp lifted its stake in Sage Therapeutics by 18.2% in the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company's stock valued at $21,127,000 after buying an additional 451,377 shares in the last quarter. Millennium Management LLC grew its holdings in Sage Therapeutics by 8.3% during the 4th quarter. Millennium Management LLC now owns 1,623,785 shares of the biopharmaceutical company's stock valued at $8,817,000 after buying an additional 124,720 shares during the last quarter. Finally, Boothbay Fund Management LLC acquired a new stake in Sage Therapeutics during the 4th quarter valued at $7,540,000. 99.22% of the stock is owned by institutional investors and hedge funds.
About Sage Therapeutics
(
Get Free ReportSage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Recommended Stories
Before you consider Sage Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sage Therapeutics wasn't on the list.
While Sage Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
